I-Tech sets its sights on large-scale Selektope® production in Europe
To satisfy increasing customer demand for antifouling coatings including Selektope® in the marine market, Swedish bio-technology innovator I-Tech AB plans to evaluate an advanced European manufacturer of active pharmaceutical ingredients and intermediates as its large-scale production partner in Europe.
Within an agreed timetable, I-Tech and its potential manufacturing partner aim to optimize and adapt I-Tech processes for production of Selektope® at scale at an existing plant. The development program is of strategic importance for I-Tech as it supports the company’s long-term aim to continuously strengthen the supply chain and maximize the delivery capability for Selektope®.
Having recently acquired the IPR and technical expertise to undertake the Selektope® synthesis, and appointed a new supply chain and logistics manager, the new initiative aims to further strengthen the I-Tech supply chain,and improve the competitive edge in its key markets.
Selektope®, chemically known as medetomidine, is an organic, non-metal compound that is very efficient at preventing barnacle fouling when used in traditional marine coating systems. Characterized by high efficacy at extremely low concentrations (0.1% w/w) with ultra-low leaching, the biocide repels barnacle settlement on ships’ hulls by temporarily stimulating the barnacle larvae’s swimming behavior. Tests have shown that antifouling coatings containing Selektope® offer superior hard fouling protection, resulting in lower water resistance and decreased fuel consumption, in addition to reduced maintenance costs.
Philip Chaabane, CEO I-TECH AB, comments: “In recent years, I-Tech has been successful in scaling up the production of its unique technology from quantities measured in kilos to a robust manufacturing platform producing at multiple tons scale. As customer demand continues to increase, it is important for I-Tech to develop redundancy as well as competitive scale in its manufacturing capability. This evaluation program supports our long-term goals for Selektope® to prosper and meet increasing demand in key markets”
Jul 09 2018
Most read
Shippax Ferry Conference - less than three weeks left. Last chance to book! (Upd. 25 Apr)
Apr 23 2024
DFDS initiates hybrid-electric ro-pax vessel design study with Incat for Channel Island tender
Apr 23 2024
The MSC Foundation, The MSC Group and Mercy Ships International join forces to build a new hospital ship
Apr 23 2024